Logo Kala Pharmaceuticals, Inc. - KALA 4.00 USD

EPS
-10.15
P/B
1.90
ROE
-430.96
Beta
-2.20

3.997 USD

3.997 USD

Daily: +6.02%
Key Metrics

EPS: -10.15

Book Value: 2.03

Price to Book: 1.90

Debt/Equity: 540.01

% Insiders: 4.116%

Estimates

Forward P/E: -0.58

Forward EPS: -6.67

 Logo About Kala Pharmaceuticals, Inc. - (KALA)

Country: United States

Sector: Health Care

Website: http://www.kalarx.com

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Exchange Ticker
NMS (United States) KALA
FRA (Germany) 27F.F

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Oct. 21, 2022 0.02
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion